Patients with HCC occurrence after DAA therapy had significantly higher age (p = 0.032), prevalence of cirrhosis (p = 0.004), history of HCC (p < 0.001), AST level (p = 0.012), FIB‐4 (p = 0.004), APRI (p = 0.006) and TSP2 (p = 0.024), along with significantly lower Alb level (p = 0.023), versus non‐HCC occurrence patients. The gene discussed is ALB; the disease is hepatocellular carcinoma.